Abstract
Innovative medicines can nowadays open new horizons for patients with life threatening diseases; but access to health innovation is a real headache for decision-makers. The therapeutic progress brought by these innovations is often linked to a heavy cost. This study aims to determine time to access in Algeria for innovative medicines. METHOD : a deep descriptive analysis of the algerian market access landscape in terms of registration, pricing, reimbursement and procurement was undertaken, then, to select the innovative medicines, a comparison between the HAS and the FDA was conducted, the registration and market access timelines were determined in Algeria and the performance against France and USA
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
